The latest report from a group financed and backed by the pharmaceutical industry “continues to misrepresent” the 340B Drug Pricing Program and its “successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive health services,” AHA Executive Vice President Tom Nickels writes today in an AHA Stat blog post. Nickels says the report “attempts to mislead the debate by comparing changes in the ‘charity care’ provided by a small sample size of 160 disproportionate share hospitals (out of 2,448 hospitals) that participate in the 340B program,” and he highlights the many benefits 340B hospitals provide to the patients and communities they serve. "We hope policymakers won’t be diverted by this self-serving report from the important job of finding solutions to bring down the exorbitant cost of many prescription drugs that is threatening the availability of life-saving medications for millions of Americans,” Nickels writes.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services recently issued new guidance implementing the Medicaid Optional Uninsured COVID-19 Testing (XXIII) Group,…
Headline
Leaders of the House Energy and Commerce and Senate Finance committees today asked Health and Human Services Secretary Alex Azar to clarify by June 10 the…
Headline
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
Headline
An estimated 9.5% of U.S. residents, or 30.7 million people, lacked health insurance when surveyed in the first six months of 2019, according to preliminary…
Perspective
On Tuesday, the Census Bureau reported that “a third of Americans now show signs of clinical anxiety or depression” due to the COVID-19 pandemic. It’s also…
Headline
Over 1,750 Medicare Part D prescription drug plans and Medicare Advantage plans with prescription drug coverage have applied to offer lower insulin costs…